Neurotoxicity Induced by Antiepileptic Drugs in Cultured Hippocampal Neurons: A Comparative Study between Carbamazepine, Oxcarbazepine, and Two New Putative Antiepileptic Drugs, BIA 2-024 and BIA 2-093 by Araújo, Inês M. et al.
Epilepsia, 45(12):1498–1505, 2004
Blackwell Publishing, Inc.
C© 2004 International League Against Epilepsy
Neurotoxicity Induced by Antiepileptic Drugs in Cultured
Hippocampal Neurons: A Comparative Study between
Carbamazepine, Oxcarbazepine, and Two New Putative
Antiepileptic Drugs, BIA 2-024 and BIA 2-093
∗Ineˆs M. Arau´jo, ∗†Anto´nio Francisco Ambro´sio, †Ermelindo C. Leal, ∗Maria Joa˜o Verdasca,∗‡Joa˜o Oliveira Malva, §Patrı´cio Soares-da-Silva, ∗Arse´lio Pato Carvalho,
and ∗Caetana Monteiro Carvalho
∗Center for Neuroscience and Cell Biology, Department of Zoology, †Center of Ophthalmology of Coimbra, IBILI,
Faculty of Medicine, and ‡Institute of Biochemistry, Faculty of Medicine, University of Coimbra, Coimbra;
and §Department of Research and Development, BIAL, S. Mamede do Coronado, Portugal.
Summary: Purpose: Newly designed antiepileptic drugs
(AEDs) are being evaluated for their efficacy in preventing
seizures and for their toxic profiles. We investigated and com-
pared the toxic effects of two dibenz[b,f ]azepine derivatives with
anticonvulsant activity, 10,11-dihydro-10-hydroxyimino-5H-
dibenz[b,f ]azepine-5-carboxamide (BIA2-024) and (S)-(-)-10-
acetoxy-10,11-dihydro-5H-dibenz[b,f ] azepine-5-carboxamide
(BIA2-093), with the structurally related compounds carba-
mazepine (CBZ) and oxcarbazepine (OXC), both in current use
for the treatment of epilepsy.
Methods: Primary rat hippocampal neurons were used to eval-
uate neuronal morphology and biochemical changes induced
by the AEDs used in this study. Immunocytochemical stain-
ing against MAP-2 was used to evaluate neuronal morphology.
Reactive oxygen species (ROS) and changes in mitochondrial
membrane potential (m) were measured by fluorescence tech-
niques. Intracellular adenosine triphosphate (ATP) levels were
quantified by high-performance liquid chromatography (HPLC).
Results: Hippocampal neurons treated for 24 h with CBZ or
OXC (300 µM) showed degeneration and swelling of neurites,
but this effect was not observed in neurons treated with BIA 2-
024 or BIA 2-093 (300 µM). ROS production also was increased
in neurons treated with OXC, but not in neurons treated with the
other AEDs. ATP levels were significantly decreased only in
neurons treated with OXC, although the energy charge was not
altered. Furthermore, OXC led to a decrease of m.
Conclusions: In all parameters assayed, OXC was more
toxic than the other AEDs used. Because the new putative
AEDs have previously been shown to have an efficacy in pre-
venting seizures similar to that of CBZ and OXC, and are
less toxic to neuronal cells, they may be considered as al-
ternatives to the current available therapies for the treatment
of epilepsy. Key Words: Neurotoxicity—Carbamazepine—
Oxcarbazepine—BIA 2-024—BIA 2-093.
Epilepsy is a common neurologic disease estimated
to affect 50 million persons worldwide. The ma-
jor antiepileptic drugs (AEDs) in current clinical use
[e.g., phenytoin (PHT), carbamazepine (CBZ), valproate
(VPA), and phenobarbital (PB), among others] have a high
efficacy in reducing seizures. An ideal AED would pre-
vent seizures without producing side effects that adversely
affect the patient’s quality of life. Unfortunately, patients
taking AEDs display a broad spectrum of undesirable side
effects. Particularly dizziness, ataxia, drowsiness, and re-
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duction of alertness occur in therapy with CBZ, in the be-
ginning of treatment and with increasing doses (1). Thus,
extensive research has focused on the design of new drugs
with anticonvulsant activity and fewer adverse effects.
New drugs have progressed in terms of longer half-lives,
greatly reduced potential for drug interactions, and general
lack of hepatic enzyme induction (2–5).
CBZ is a dibenz[b,f ]azepine derivative (5H-
dibenz[b,f ]azepine-5-carboxamide (6) that, since its
introduction for clinical treatment of epileptic seizures,
has become the most frequently prescribed first-line
drug. Besides the fact that a significant percentage of
affected individuals do not respond to treatment with
CBZ, this drug has the disadvantage of inducing hepatic
microsomal enzymes that cause self-induction of its
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own metabolism. Moreover, its metabolites (particularly
epoxides) have been held responsible for the general
and neuronal toxicity of CBZ. Oxcarbazepine (OXC) is
an analogue of CBZ, with comparable anticonvulsant
efficacy, in which a keto group has been added to the
position 10 of the azepine ring. This modification results
in important differences in the metabolism of the two
drugs. It has the advantage of a lower incidence of allergic
reactions and enzyme induction. In combined therapy
with other AEDs, OXC is usually better tolerated than
CBZ (7).
10,11-Dihydro-10-hydroxyimino-5H-dibenz[b,f ]azep
ine-5-carboxamide (BIA 2-024) and (S)-(-)-10-acetoxy-
10,11-dihydro-5H-dibenz[b,f ]azepine-5-carboxamide (B
IA 2-093) are representative of a new series of com-
pounds (8,9), structurally related to CBZ and OXC,
with anticonvulsant activity, as determined by maximal
electroshock stimulation (9,10). As newly developed
drugs should be less toxic than already existing drugs,
these two compounds were specifically designed to
circumvent their further degradation to toxic metabolites,
such as epoxides, without losing anticonvulsant potency.
Several studies can be found in the literature regarding
the toxicity of AEDs to neuronal cells. Some reports show
that CBZ is able to induce apoptosis in cultured cerebel-
lar granule cells (11–13). In a previous study, we showed
that OXC and CBZ can be toxic to cultured hippocampal
neurons (14), showing patterns of neuronal deterioration,
mainly in cells exposed to high concentrations, and also
showing increased activity of caspase-3–like enzymes,
in the case of OXC. We also have seen some morpho-
logic changes (nuclear condensation) in neurons exposed
to high concentrations of either BIA 2-024 or BIA 2-093,
suggesting apoptosis, although the extent of the insult was
much less than that observed with CBZ or OXC. Recently,
Pavone and Cardile (15) described the effects of CBZ and
OXC on astrocyte cultures and showed decreased toler-
ance by cortical astrocytes to high concentrations of these
and other AEDs.
Within this scenario, we found important to compare the
toxicity profiles of the new putative AEDs, BIA 2-024 and
BIA 2-093, with those of currently used and structurally
similar AEDs, CBZ and OXC. We chose cultured hip-
pocampal neurons as a model, given that the hippocampal
formation is one of the most affected brain regions during
status epilepticus. In this study, we further investigated
the toxic effect caused by AEDs in cultured neurons. We
focused on parameters related to apoptosis-like cell death
and markers for mitochondrial dysfunction, which com-
promises the energy status of the cell and impairs neuronal
survival.
MATERIALS AND METHODS
Cell culture
Hippocampal neurons were dissociated from hip-
pocampi of E18–E19 Wistar rat embryos, after treatment
with trypsin (2.0 mg/ml, 15 min, 37◦C) and deoxyribonu-
clease I (0.15 mg/ml) in Ca2+-free and Mg2+- free Hank’s
balanced salt solution (137 mM NaCl, 5.36 mM KCl,
0.44 mM KH2PO4, 0.34 mM Na2PO4 2H20, 4.16 mM
NaHCO3, 5 mM glucose, 1 mM sodium pyruvate, 10 mM
HEPES, pH 7.4). The cells were cultured in serum-free
Neurobasal medium, supplemented with B27 supplement,
glutamate (25 µM), glutamine (0.5 mM), and gentamicin
(0.12 mg/ml), as described previously (16). Cultures were
kept at 37◦C in a humidified incubator in 5% CO2/95% air,
for 7 to 8 days before the experiments, the time required
for maturation of hippocampal neurons.
For morphology studies and 5,5’,6,6’-tetrachloro-
1,1’,3,3’- tetraethyl-benzimidazolylcarbocyanine iodide
(JC-1) confocal microscopy analysis, cells were plated in
coverslips at 0.045 × 106 cells/cm2. For reactive oxygen
species (ROS) production experiments and JC-1 fluori-
metric analysis, cells were plated in coverslips at 0.2 × 106
cells/cm2. For adenine nucleotide determinations, cells
were plated in multiwell plates at 0.1 × 106 cells/cm2.
Exposure of hippocampal neurons to drugs
The hippocampal neurons were exposed to drugs for 24
h. The stock solutions of the drugs [prepared in dimethyl-
sulfoxide (DMSO)] were diluted in small aliquots of con-
ditioned medium (medium in which the cells were cultured
until the experiment) and then added back to the corre-
sponding well. All drugs were used at a concentration of
300 µM. The presence of DMSO did not cause any dif-
ference or toxicity compared with cultures that were not
treated with DMSO. The final concentration of DMSO
used (0.1%) was without consequences to cell viability.
Morphology studies
Neuronal morphology was evaluated after an immuno-
cytochemical labelling of the hippocampal neurons by us-
ing an anti–microtubule-associated protein 2 (MAP-2) an-
tibody. After incubation of cultured hippocampal neurons
with the drugs for 24 h, the culture medium was removed,
the cells were washed 3 times with phosphate buffered
saline (PBS), and fixed with 4% paraformaldehyde, at
room temperature, for 30 min. After three washes with
PBS, nonspecific binding was blocked with 3% bovine
serum albumin (BSA) in PBS. Cells were then incubated
with anti–MAP-2 (1:200) at room temperature for 1 h.
After three washes with PBS, cells were incubated with a
secondary antibody, anti-mouse immunoglobulin G (IgG)
labelled with Alexa Fluor 594 (1:200), at room temper-
ature, for 1 h. Finally, coverslips were mounted by us-
ing a Prolong Antifade Kit and after drying, the neurons
were visualized with confocal fluorescence microscopy
(Bio-Rad MRC 600 B10-Rad Laboratories, Hercules, CA,
U.S.A.).
Measurement of ROS production
ROS production in populations of hippocampal neurons
was measured by using 2’,7’-dichlorodihydrofluorescein
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diacetate (DCFH2-DA), a cell-permeant probe for
ROS, which is deesterified within the cells to
DCFH2. The accumulated DCFH2 becomes fluores-
cent when it is oxidized to dichlorofluorescein (DCF),
thus detecting the formation of ROS or intracellular
peroxides.
Hippocampal neurons plated on coverslips at a den-
sity of 0.2 × 106 cells/cm2 were incubated with 5 µM
DCFH2-DA in Krebs buffer (132 mM NaCl, 4 mM KCl,
1.4 mM MgCl2, 1 mM CaCl2, 6 mM glucose, 10 mM
HEPES-Na, pH 7.4) for 30 min, at 37◦C, in the dark. The
coverslips were rinsed with Krebs buffer and mounted in
a special holder (Perkin-Elmer L2250008), in a tempe-
rature-controlled cuvette with magnetic stirring. The flu-
orescence was monitored at 37◦C with a Spex Fluo-
romax spectrofluorometer, with excitation at 502 nm
and emission at 550 nm, by using 3 nm slits. The in-
crease in fluorescence due to oxidation of DCFH2 to
DCF was recorded for 120 s, and the slope was calcu-
lated with the values of fluorescence arbitrary units at
20 and 100 s. Results are expressed as percentage of
control.
Assessment of mitochondrial depolarization
JC-1 is a cationic carbocyanine dye that accumulates in
mitochondria and is suitable for assessing changes in mi-
tochondrial membrane potential (m). The dye exists as a
monomer at low concentrations and yields green fluores-
cence. At higher concentrations, JC-1 forms aggregates
that exhibit a broad excitation spectrum and maximum
emission at ∼590 nm. The JC-1 red/green fluorescence
ratio has been used as a tool to estimate changes in m
(17).
Neurons were loaded with 3 µM JC-1 for 15 min, at
37◦C in the dark, after exposure to the AEDs for 24 h.
For spectrofluorimetric analysis of JC-1 red/green flu-
orescence ratio, the fluorescence was monitored during
700 s, with excitation at 490 nm and emission at 535
and 595 nm. In the end of each experiment, FCCP (2.5
µM) plus oligomycin (1 µg/ml) were added to com-
pletely depolarize mitochondria and validate the assay;
FCCP is a proton ionophore known to uncouple the pro-
ton gradient across the inner mitochondrial membrane,
and oligomycin, which inhibits proton transport through
the ATP synthase, prevents maintenance of m by ATP
synthase reversal and glycolytic ATP hydrolysis (18), thus
eliminating m artifacts. Red/green ratios were obtained
by dividing the signal at 595 nm (aggregate) by the signal
at 535 nm (monomer) and normalizing to a starting value
of 1, for comparison between the various conditions. Re-
sults are presented as the rate of decrease in red/green
ratio signal (17). For microscopy analysis, after loading
the cells with 3 µM JC-1, for 15 min at 37◦C in the dark,
the coverslips were observed with laser scanning confo-
cal microscopy in a Bio-Rad MRC 600 confocal micro-
scope. Neurons were excited at 488 nm, and emission was
recorded at 530 and 590 nm.
Determination of adenine nucleotides
Intracellular adenine nucleotides, ATP, adenosine
diphosphate (ADP), and adenosine monophosphate
(AMP) from hippocampal neurons were determined by
reversed-phase HPLC, as previously described (19), after
cell extraction. After exposure of hippocampal neurons
to drugs for 24 h, cells were lysed in 0.3 M perchloric
acid and collected. Extraction was followed by centrifu-
gation at 15,800 g for 5 min. The pellet was solubilized
in 0.1 M NaOH for total protein analysis by the Brad-
ford/Biorad method. The supernatant was neutralized with
3.3 M KOH in 1.67 M Tris and centrifuged at 15,800 g
for 10 min. The potassium perchlorate precipitate was
discarded, and the resulting supernatants were stored at
–80◦C. Adenine nucleotide content was determined by
reverse-phase HPLC, by using a Beckman System Gold,
consisting of a binary pump (126 Binary Pump Model)
with a 166 Variable UV detector. A Lichrospher 100 Rp-
18 column (Merck) was used. The mobile phase was com-
posed of 100 mM KH2PO4, pH 6.5, 1% methanol, at a
flow rate of 1.1 ml/min. Absorbance was monitored at
254 nm.
Peak identity was determined by the retention time com-
pared with standards. The amounts of ATP, ADP, and AMP
were determined by a concentration standard curve. ATP-
content values were normalized according to the protein
concentration for each sample. The energy charge (EC) of
the hippocampal cells was calculated by using the follow-
ing formula (20):
EC = (ATP + 0.5 ADP)/(ATP + ADP + AMP)
Chemicals
BIA 2-024, BIA 2-093, CBZ, and OXC were obtained
from BIAL (S. Mamede do Coronado, Portugal). Neu-
robasal medium, B27 supplement, gentamicin and trypsin
(USP grade) were purchased from GIBCO BRL (Life
Technologies, Scotland). Glutamate, glutamine, DNase
(DN-25), anti-MAP-2, and trypan blue were purchased
from Sigma Chemical (St. Louis, MO, U.S.A.). DCFH2-
DA, JC-1, and anti-mouse IgG labelled with Alexa Fluor
594 were purchased from Molecular Probes, Leiden,
The Netherlands. BSA was purchased from Calbiochem-
Boerhringer (San Diego, CA, U.S.A.). All other reagents
were from Sigma Chemical or from Merck-Schuchardt,
Germany.
CBZ, OXC, BIA 2-024, BIA 2-093, JC-1, and DCFH2-
DA stock solutions were prepared in DMSO. The solutions
of all other reagents were prepared in ultrapurified water.
Statistical analysis
Data are expressed as mean ± SEM. Statistical signif-
icance was determined by using an analysis of variance
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(ANOVA), followed by Dunnet’s posttest, as indicated in
the figure legends.
RESULTS
Evaluation of the effect of antiepileptic drugs on the
morphology of cultured rat hippocampal neurons
Previous studies showed that AEDs like PHT, CBZ,
or OXC are toxic to neurons in culture (11–14) and
also to cultured astrocytes (15). Indeed, our group pre-
viously tested different concentrations of CBZ and OXC
(from 10 to 300 µM) and observed that cultured hip-
pocampal neurons treated with 300 µM OXC, CBZ, BIA
2-024, or BIA 2-093 for 24 h show apoptosis-like fea-
tures (e.g., condensed chromatin and nuclei), and OXC
is clearly more toxic than the other AEDs tested (14).
At these concentrations, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazollum bromide (MTT) reduction was sig-
nificantly decreased by OXC and CBZ (62.5 ± 3.2% and
75.4 ± 2.3%, respectively; p < 0.01) and nonsignificantly
decreased by BIA 2-024 or BIA 2-093 (14). The number
of apoptotic neurons is increased by treatment with OXC
or CBZ (39.3 ± 3% or 31.3 ± 3%; p < 0.01, respectively;
above 13% in control cultures), whereas BIA 2-024 or
BIA 2-093 only slightly increases the number of apop-
totic neurons (14). In the present work, we further investi-
gated the mechanisms of the toxic effect caused by these
AEDs. The effects of high concentrations (300 µM) of
OXC, CBZ, BIA 2-024, or BIA 2-093 on the morphology
of cultured hippocampal neurons, for a 24 h exposure, as
assessed by anti–MAP-2 immunocytochemistry (Fig. 1),
confirm the previous results. Changes in neuronal mor-
phology were notorious when cells were treated with OXC
(compare Fig. 1A and B, and Fig. 1F and G): the fine neu-
ritic network observed in untreated neurons was signifi-
cantly affected in OXC-treated cultures, and the remain-
ing neurites were swollen and with less punctate synaptic
varicosities (Fig. 1B and G). CBZ was not as effective as
OXC in inducing morphologic changes to hippocampal
neurons, although some damage is evident, and neurites
appear to be retracting (Fig. 1C). BIA 2-024 (Fig. 1D) and
BIA 2-093 (Fig. 1E and H) did not induce any apparent
neuronal damage, as the neuronal network appears to be
well preserved.
OXC increases reactive oxygen species production
The formation of ROS in cultured hippocampal neurons
was studied by following DCF fluorescence on exposure
to AEDs for 24 h (Fig. 2). OXC (300 µM) induced a sig-
nificant increase in ROS production to 221.7 ± 40.0% of
the control (p < 0.001). Lower concentrations of OXC
(50 and 100 µM) did not significantly increase ROS pro-
duction (data not shown). ROS production in cells treated
with CBZ (300 µM), BIA 2-093 (300 µM), or BIA 2-
024 (300 µM) was also not increased, as compared with
control (Fig. 2).
Effect of AEDs in intracellular ATP levels and energy
charge of cultured hippocampal neurons
Adenine nucleotide (ATP, ADP, and AMP) levels were
determined by reverse-phase HPLC (Fig. 3). Exposure to
OXC (300 µM) for 24 h resulted in a significant decrease
of intracellular ATP levels from 50.4 ± 2.6 nmol/mg pro-
tein (control cultures) to 35.7 ± 3.0 nmol/mg protein (p <
0.05). The other AEDs did not cause a significant varia-
tion in intracellular ATP levels. However, the EC was not
significantly decreased in OXC-treated cultures (0.85 ±
0.034) relative to control cultures (0.88 ± 0.026) or with
the other AEDs.
OXC decreases mitochondrial membrane potential
Confocal microscopy imaging showed that the red flu-
orescence of JC-1 aggregate form is decreased in OXC-
treated cultures, whereas the green monomer fluorescence
is greatly increased, indicative of mitochondrial depolar-
ization (Fig. 4). In cultures treated with CBZ, BIA 2-024,
or BIA 2-093, the aggregate fluorescence is similar to that
of untreated cultures, and the monomer fluorescence is
faint.
In attempting to quantify the JC-1 red/green fluores-
cence ratio, it was observed that this ratio decreased with
time (400 s) in all situations, which was likely to be due
to photobleaching. The addition of FCCP (2.5 µM) plus
oligomycin (1 µg/ml) significantly decreased m in all
conditions. In cells treated with 300 µM OXC for 24 h,
the JC-1 ratio decreased in a faster way, accounting for
a significant decrease in m during the time-drive fluo-
rescence monitoring: the rate of decrease of the red/green
fluorescence ratio over time was significantly higher in
OXC-treated neurons (133.4 ± 10% of the control; p <
0.05; Fig. 5) than in control conditions. Neither CBZ nor
the new putative AEDs had a significant effect on m.
DISCUSSION
In this work, we show that OXC, at high concentrations,
is toxic to cultured hippocampal neurons, triggering mech-
anisms that result in decreased intracellular ATP levels and
increased ROS, compromising cell survival. We observed
significant neurotoxic changes after treatment with OXC,
which are not observed with treatment with the two new
putative AEDs, BIA 2-024 and BIA 2-093, or with CBZ,
thus sustaining the concept that this new putative AEDs
are less toxic than currently used AEDs. These results are
in agreement with and extend the observations in previ-
ous studies by our group (14), in which it was shown that
OXC is toxic to cultured hippocampal neurons and that
BIA 2-024 and BIA 2-093 are less toxic than the related
compounds, CBZ and OXC, which toxicity is detected at
concentrations as low as 50–100 µM.
When dealing with a disease such as epilepsy (21),
which is a life-long condition and requires continu-
ous treatment after diagnosis, bioaccumulation of AEDs
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FIG. 1. Changes in the morphology of cultured hippocampal neurons treated with antiepileptic drugs for 24 h, as assessed by anti–MAP-
2 immunocytochemistry. A: Control culture. B: 300 µM oxcarbazepine (OXC). C: 300 µM carbamazepine (CBZ). D: 300 µM BIA 2-024.
E: 300 µM BIA 2-093. All at ×600 magnification. F: Control culture. G: 300 µM OXC. H: 300 µM BIA-2-093. All at ×900 magnification.
At higher magnification (F–H), the toxic effect of OXC is clear in the swollen and shorter neurites (G) and in the loss of the fine neuritic
network. BIA 2-024 (D) or BIA 2-093 (E, H) did not induce such modifications (similar to control culture).
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FIG. 2. Reactive oxygen species (ROS) production in cultured
hippocampal neurons after treatment with antiepileptic drugs for
24 h. ROS production was assessed by following the oxidation of
the cell-permeant fluorescent probe, DCFH2-DA, to the fluores-
cent form DCF. Each drug was used at 300 µM. The results are
presented as percentage of control (no treatment), by using ar-
bitrary fluorescence units at an excitation wavelength of 502 nm,
and represent the mean ± SEM of at least five independent exper-
iments. ∗∗∗p < 0.001, significantly different from control; Dunnett’s
posttest.
cannot be excluded, and the plasma levels of the drug can
surpass the therapeutic dose; hence the interest of study-
ing the effect in neuronal survival of high concentrations
of AEDs. Pavone and Cardile (15) characterized the effect
of various concentrations of CBZ and OXC (ranging from
1 to a 100 µg/ml), as well as other AEDs, on the viability
of cultured cortical astrocytes, showing increased cellular
stress. To our knowledge, little is known about the toxi-
city triggered by AEDs in neurons. High concentrations
of CBZ were shown to be neurotoxic in cultured cerebel-
lar neurons (11–13) and in cultured hippocampal neurons
(14). OXC also was described to be toxic to hippocampal
neurons (14). It is very important to assess the neurotoxic
profile of AEDs because metabolic failure due to drug in-
teraction and/or hepatic dysfunction or renal failure might
FIG. 3. Intracellular adenosine triphosphate (ATP) levels in cul-
tured hippocampal neurons after treatment with antiepileptic
drugs for 24 h. Each drug was used at 300 µM. The results are
presented as nanomoles per milligram protein and represent the
mean ± SEM of at least four independent experiments. ∗p < 0.05,
significantly different from control; Dunnett’s posttest.
lead to an increase in plasma levels of the drug, and thus
the interest in choosing a therapy with as few toxic effects
as possible to neuronal cells.
We found that OXC had a strong deleterious effect in the
morphology of cultured hippocampal neurons: the neu-
rites became swollen and shorter, and the network of fine
processes that is observed in control cultures was greatly
reduced. The CBZ effect was not as dramatic as that of
OXC, although the damage in neuronal cultures was clear.
Treatment of cultures with OXC (100 µM) did not cause
an apparent retraction and swelling of neurites (data not
shown), although a decrease of MTT reduction and in-
crease in the number of apoptotic-like nuclei were already
observed at this concentration (14). Apparently, morpho-
logic changes are secondary to biochemical detection of
neurodegeneration, as when the MTT reduction is signif-
icantly decreased or the appearance of apoptotic-like nu-
clei is clearly higher, but still no morphologic changes at
the neurite network level are yet visible. The hippocam-
pal cultures treated with BIA 2-024 and BIA 2-093 did
not show evident morphologic markers of neurodegener-
ation, suggesting that these drugs are not as toxic as OXC
or CBZ. Previous work with BIA 2-024 and BIA 2-093
showed that at the same concentration used in the present
study (300 µM), BIA 2-093 significantly decreases MTT
reduction by hippocampal neurons in culture, but BIA 2-
024 did not (14). However, in the same study, the new
putative AEDs did not cause an increase in caspase-3–
like enzymes activity, as OXC or CBZ did, and neuronal
morphology appears to be intact, as we observed.
Mitochondria are central players in the metabolic pro-
cesses of eukaryotic cells, having a critical role in ATP
synthesis. Additionally, mitochondria are highly involved
in other cellular processes besides energy production, such
as intracellular Ca2+ buffering and cell death. We screened
for the effect of AEDs in intracellular ATP levels and the
EC of cultured hippocampal neurons exposed to these
drugs. Only treatment with OXC but not with the other
AEDs caused a decrease in intracellular ATP levels. Al-
though a consistent and significant decrease in intracellu-
lar ATP levels is caused by OXC exposure, the decrease
observed is not massive, and thus this is not traduced by
a significant decrease in energy charge, which might be
explained by the fact that apoptosis rather than necrosis is
occurring. Our current data and previous work point to a
situation of apoptosis. ATP is required for apoptotic cell
death, and depletion of the intracellular ATP levels and a
dramatic decrease of the cell energy charge would cause
a shift from apoptosis to necrotic cell death (22), which
does not seem to be the case. Likewise, an increase in ROS
production as well as a decrease in m, observed only in
OXC-treated neurons, suggests that the toxic effects of
OXC might be mediated by a mitochondrial pathway, be-
cause the majority of ROS generated in the cells are of
mitochondrial origin.
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FIG. 4. Effect of antiepileptic drug treat-
ment for 24 h on mitochondrial membrane
potential (m) in primary hippocampal cul-
tures. Cultured hippocampal neurons were
loaded with 3 µM JC-1, 15 min before imag-
ing experiments. Under normal conditions,
JC-1 aggregates emit red fluorescence; a
decrease in m results in an increase in the
JC-1 monomer, which emits green fluores-
cence. A: Control culture. B: Oxcarbazepine
(OXC). C: Carbamazepine (CBZ). D: BIA
2-024. E: BIA 2-093. 300 µM each; ×600
magnification.
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FIG. 5. Changes in mitochondrial membrane potential (m) of
cultured hippocampal neurons after treatment with antiepileptic
drugs for 24 h. Each drug was used at 300 µM. The figure rep-
resents changes in the rate of decrease of JC-1 red/green fluo-
rescence ratio signal. The results are presented as percentage of
control and represent the mean ± SEM of at least four indepen-
dent experiments. ∗p < 0.05, significantly different from control;
Dunnett’s posttest.
OXC rapidly undergoes reduction of the carbonyl group
in the liver, to form the active agent 10,11-dihydro-10-
hydroxycarbamazepine, and is thought to be a good al-
ternative to CBZ in the treatment of epilepsy, because
its metabolism does not involve formation of an epoxide
metabolite, thus being less toxic. Compared with the par-
ent compound (CBZ), hepatic microsomal enzyme induc-
tion and autoinduction are greatly reduced, and the clinical
efficacy of OXC compares favorably with that CBZ in clin-
ical trials (5). OXC has fewer side effects and reduced po-
tential for drug interaction in patients that did not respond
well to CBZ therapy. However, of all the drugs tested in this
study, OXC was the more toxic drug in all the parameters
assayed. In vitro, OXC was not converted to other metabo-
lites in cultured hippocampal neurons (data not shown),
suggesting that the toxic effect of treatment with OXC in
vitro is due to OXC itself and not to its metabolites. Being
so, because in vivo OXC is rapidly metabolized to 10,11-
dihydro-10-hydroxycarbamazepine, OXC will not reach
the brain unless metabolic impairment occurs, and hepatic
dysfunction is not uncommon in patients with epilepsy,
which can often result from the AED therapy itself as an
undesirable side effect. Thus care should be taken when
administering OXC, because it proved to be toxic to cul-
tured hippocampal neurons at concentrations not far from
the therapeutic levels (14).
Within this scenario, because the two new putative
AEDs have been shown to have efficacy in preventing
seizures similar to that of CBZ and OXC (8,9), being less
toxic to neuronal cells, there are advantages in considering
these new drugs as possible alternatives to the current ther-
apies available for the treatment of epilepsy. BIA 2-093
proved to be safe in a double-blind, placebo-controlled
clinical trial in healthy male volunteers (23).
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